share_log

Eli Lilly and Co | 8-K: Eli Lilly Announces Anat - Ashkenazi to Resign as Executive Vice President and Chief Financial Officer

Eli Lilly and Co | 8-K: Eli Lilly Announces Anat - Ashkenazi to Resign as Executive Vice President and Chief Financial Officer

禮來 | 8-K:禮來宣佈Anat - Ashkenazi將辭去執行副總裁兼首席財務官一職
美股sec公告 ·  07/10 08:44
Moomoo AI 已提取核心訊息
Eli Lilly and Company reported a significant change in its executive team with the resignation of Anat Ashkenazi as the executive vice president and chief financial officer, effective June 5, 2024. Ashkenazi has decided to leave the pharmaceutical industry to pursue a different career path. Following her departure, Gordon Brooks, who has been with Eli Lilly for 29 years and currently serves as the group vice president, controller and corporate strategy, will take over as the interim chief financial officer starting July 15, 2024. Brooks has a diverse background within the company's finance organization, including roles as senior vice president, chief procurement officer, and general auditor. The company has confirmed that there are no familial or transactional relationships influencing Brooks' appointment. Ashkenazi will assist with the transition until the end of July 2024.
Eli Lilly and Company reported a significant change in its executive team with the resignation of Anat Ashkenazi as the executive vice president and chief financial officer, effective June 5, 2024. Ashkenazi has decided to leave the pharmaceutical industry to pursue a different career path. Following her departure, Gordon Brooks, who has been with Eli Lilly for 29 years and currently serves as the group vice president, controller and corporate strategy, will take over as the interim chief financial officer starting July 15, 2024. Brooks has a diverse background within the company's finance organization, including roles as senior vice president, chief procurement officer, and general auditor. The company has confirmed that there are no familial or transactional relationships influencing Brooks' appointment. Ashkenazi will assist with the transition until the end of July 2024.
艾黎利(Lilly)公司報告其高管團隊出現重大變動,Anat Ashkenazi已辭去執行副總裁兼首席財務官職位,將於2024年6月5日生效。 Ashkenazi決定離開藥品行業,追求不同的職業道路。在她離職後,Gordon Brooks將接替她的工作,從2024年7月15日開始擔任臨時首席財務官。 Brooks在Eli Lilly工作了29年,目前擔任集團副總裁、人形機器人-電機控制器和公司策略。在公司金融組織中,Brooks擁有豐富的背景,包括資深副總裁、首席採購官和常務審計。該公司已經確認沒有任何家庭或交易關係影響Brooks的任命。Ashkenazi將協助過渡,直到2024年7月底。
艾黎利(Lilly)公司報告其高管團隊出現重大變動,Anat Ashkenazi已辭去執行副總裁兼首席財務官職位,將於2024年6月5日生效。 Ashkenazi決定離開藥品行業,追求不同的職業道路。在她離職後,Gordon Brooks將接替她的工作,從2024年7月15日開始擔任臨時首席財務官。 Brooks在Eli Lilly工作了29年,目前擔任集團副總裁、人形機器人-電機控制器和公司策略。在公司金融組織中,Brooks擁有豐富的背景,包括資深副總裁、首席採購官和常務審計。該公司已經確認沒有任何家庭或交易關係影響Brooks的任命。Ashkenazi將協助過渡,直到2024年7月底。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息